6
6 Management of chronic heart failure
Pages 31–42 · open in PDF
Recommendations in this section
- Class ILevel AAn SGLT2-I (dapagliflozin or empagliflozin) is recommended in patients with symptomatic HF independent of LVEF to reduce the risk of HFH or CV death.
- Class ILevel AAn MRA (sMRA for HFrEF and sMRA/nsMRA for HFpEF) is recommended in patients with symptomatic HF independent of LVEF to reduce the risk of HFH or CV death.
- Class ILevel ADynamic individualized dosing of loop diuretics according to volume status is recommended in patients with HF and signs and/ or symptoms of congestion to alleviate HF symptoms, improve exercise capacity, and reduce the risk of HFH.
- Class ILevel CUptitration of FMT at least every 1–2 weeks in patients with HF, guided by symptoms, vital signs, and laboratory findings, to achieve optimal target doses shown to be efficacious in RCTs is recommended to reduce the risk of HFH or death.
- Class ILevel CContinuation of FMT at the highest tolerated doses is recommended in all patients with HF, including those who become asymptomatic or with LVEF improvement, in order to reduce the risk of HFH and death.
- Class ILevel AA beta-blocker is recommended in stable patients with symptomatic HFrEF to reduce the risk of HFH and death.
- Class ILevel AAn ACE-I or ARNI is recommended in patients with symptomatic HFrEF to reduce the risk of HFH and death.
- Class ILevel B1Switching from an ACE-I or ARB to an ARNI is recommended in patients with symptomatic HFrEF to reduce the risk of HFH and death.
- Class ILevel AAn ARB is recommended in patients with symptomatic HFrEF to reduce the risk of HFH and CV death if they are unable to tolerate an ACE-I or ARNI.
- Class IIaLevel B1A cardiac glycoside (digoxin or digitoxin) should be considered in patients with symptomatic HFrEF with LVEF ≤40%, despite optimal FMT, to reduce the risk of HFH.
- Class IIaLevel B1Ivabradine should be considered for patients with symptomatic HFrEF, LVEF ≤ 35%, in sinus rhythm, resting heart rate >70 b.p.m., on the highest tolerated ACE-I/ARNI, MRA, SGLT2-I, and beta-blockers to reduce the risk of HFH or CV death.
- Class IIaLevel CIvabradine should be considered in patients with symptomatic HFrEF, LVEF ≤ 35%, in sinus rhythm, who are unable to tolerate a beta-blocker, on the highest tolerated ACE-I/ARNI and MRA to reduce the risk of HFH or CV death.
- Class IIaLevel B2Hydralazine and isosorbide dinitrate should be considered in self-identified black patients with symptomatic HFrEF with LVEF ≤ 40% on top of optimal FMT to reduce the risk of HFH and death.
- Class IIbLevel CHydralazine and isosorbide dinitrate may be considered in patients with symptomatic HFrEF with LVEF ≤ 40% who cannot tolerate ARNI, ACE-I, or ARB to reduce the risk of HFH and death.
- Class IIbLevel B1Vericiguat may be considered in patients with symptomatic HFrEF and LVEF <45% despite treatment with optimal FMT to reduce the risk of HFH and CV death.
- Class IIbLevel CGradual discontinuation of FMT under frequent clinical, laboratory, and imaging surveillance may be considered in highly selected patients who are asymptomatic with complete normalization of LV function and volume as well as natriuretic peptide levels after specific treatment of reversible causes of HF, in order to accommodate patient preference.
- Class IIbLevel CACE-I/ARB/ARNI may be considered in patients with symptomatic HFpEF to reduce the risk of HFH.
- Class ILevel AAn ICD is recommended in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability (secondary prevention), and who are expected to survive for >1 year with good functional status, in the absence of reversible causes, or unless the ventricular arrhythmia has occurred <48 h after an MI, to reduce the risk of sudden death and all-cause death.
- Class ILevel B1An ICD is recommended in patients with symptomatic HFrEF (NYHA class II/III) of an ischaemic aetiology (unless they have had an MI in the prior 40 days), and an LVEF ≤35% despite ≥3 months of optimal FMT, provided they are expected to survive longer than 1 year with good functional status, to reduce the risk of sudden death and all-cause death.
- Class IIaLevel B1An ICD should be considered in patients with symptomatic HFrEF (NYHA class II/III) of a non-ischaemic aetiology, and an LVEF ≤35% despite ≥3 months of optimal FMT, provided they are expected to survive longer than 1 year with good functional status, to reduce the risk of sudden death and all-cause death.
- Class IIaLevel CPrior to generator replacement for CIEDs, a shared decision-making process between the patient and a cardiologist experienced in CIEDs and HF should be considered to ensure that the balance between risks and benefits still favour a CIED.
- Class IIbLevel CA wearable cardioverter-defibrillator may be considered in patients with HF who are at risk of sudden cardiac death for a limited period in order to increase survival as a bridge to decision for permanent ICD implantation or while listed for heart transplantation.
- Class IIILevel B1ICD implantation for primary prevention is not recommended within 40 days of an MI as implantation during this period does not improve prognosis.
- Class IIILevel CICD implantation is not recommended in patients in NYHA class IV with severe symptoms refractory to pharmacological therapy unless they are candidates for CRT, a ventricular assist device, or heart transplantation.
- Class ILevel ACRT is recommended in patients with symptomatic HFrEF, LVEF ≤ 35%, despite optimal FMT, in SR with LBBB and QRS duration ≥ 150 ms in order to improve symptoms and reduce the risk of hospitalizations and death.
- Class IIaLevel B1An upgrade to CRT should be considered in patients with an LVEF ≤ 35% who have received a conventional pacemaker or an ICD and subsequently develop worsening HF despite optimal FMT and who have a significant proportion of RV pacing in order to reduce the risk of HFH or death.
- Class IIaLevel B1CRT, rather than RV pacing, should be considered in patients with HFrEF regardless of NYHA class or QRS width who have an indication for ventricular pacing for high-degree AV block in order to reduce the risk of HFH and death.
- Class IIaLevel CCRT should be considered in patients with symptomatic HFrEF, LVEF ≤ 35%, despite optimal FMT, who are in SR with non-LBBB QRS morphology and QRS duration ≥ 150 ms in order to improve symptoms and reduce morbidity and death.
- Class IIaLevel CCRT should be considered in patients with symptomatic HFrEF, LVEF ≤ 35%, despite optimal FMT, who are in SR with LBBB QRS morphology and QRS duration of 130–149 ms in order to improve symptoms and reduce morbidity and death.
- Class IIbLevel CCRT may be considered in patients with symptomatic HFrEF, LVEF ≤ 35%, despite optimal FMT, who are in SR with non-LBBB QRS morphology and QRS duration of 130–149 ms in order to improve symptoms and reduce morbidity and death.
- Class IIbLevel CInitiation of FMT and planning for CRT implantation may be considered simultaneously in patients with symptomatic HFrEF, an LBBB with QRS ≥150 ms, and LVEF ≤35%, to improve symptoms and reduce morbidity and death, although reassessment of LVEF should be conducted prior to CRT implantation.
- Class IIILevel ACRT is not recommended in patients with a QRS duration <130 ms who do not have an indication for pacing due to high-degree AV block.
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 31 · PDF
cardiac implantable electronic device; CMR, cardiac magnetic resonance; ECG, electrocardiogram; HFrEF, heart failure with reduced ejection fraction; LBBB, left bundle branch block; PET, positron emission tomography; PMT, pacemaker tachycardia; PVC, premature ventricular contraction; RBBB, right bundle branch block; RV, right ventricular; SVT, supraventricular tachycardia; VT, ventricular tachycardia; WHF, worsening heart failure.
6. Management of chronic heart failure
Importantly, AMT and GDIT based on the underlying cause of HF, phenotypical characteristics, and comorbidities are discussed in other sections.
6.1. Guideline-directed medical therapy for heart failure
6.1.1. Goals of pharmacotherapy for patients with heart failure
The Task Force have decided to introduce the terms FMT and AMT, as described in Section 3 (Figure 3). Together FMT and AMT cover GDMT. For HFrEF, FMT currently includes beta-blockers, ACE-Is/ARNIs/ARBs, MRAs, and SGLT2-Is, whereas for HFpEF it includes SGLT2-Is and MRAs.
Pharmacotherapy remains the cornerstone of treatment for stage C HF and should be implemented at doses used in RCTs in patients with HF before considering device therapy, and alongside non-pharmacological interventions (Figure 1 and Table 11). There are three major goals of treatment for patients with HF: (i) reduction in mortality; (ii) prevention of recurrent
Figure 9 Diagnosing arrhythmia-associated heart failure and heart failure with abnormal cardiac conduction. AF, atrial fibrillation; CIED,
Page 32 · PDF
32 hospitalizations due to worsening HF (WHF); and (iii) improvements in clinical status, functional capacity and QoL. The recommendations for each treatment depending on LVEF are summarized below. Overall, there are no sex differences in recommendations for HF pharmacotherapy. In this section, we address the management of predominantly left-sided HF. Management of right-sided HF is covered comprehensively in a recent HFA consensus paper.48
Mineralocorticoid receptor antagonists and SGLT2-Is are recommended for all symptomatic patients with HF, regardless of LVEF, as these drugs reduce mortality and the risk of HFH. The recommended doses of these drugs are given in Table 11. Other agents can be used in selected patients.
6.1.2.1. Sodium–glucose co-transporter 2 inhibitors The SGLT2-Is dapagliflozin and empagliflozin have been shown to reduce the composite endpoint of HFH or CV mortality in symptomatic ambulatory patients with HF.241–245 Although there were consistent reductions in the primary endpoint across the LVEF ranges studied, the individual endpoint of CV mortality was only reduced in HFrEF.44,241,246 Thus, it is recognized that in HFpEF the reduction in the primary endpoint is driven by a reduction in HFH. The guideline Task Force has decided to base recommendations on the primary endpoints. SGLT2-Is also improve QoL.247,248 Common side effects include genital and urinary infections. A mild initial decline in eGFR is expected, but long-term kidney function is improved.249–253 Practical guidance in the use and initiation of SGLT2-Is are provided in Supplementary material online, Table S9. The use of SGLT2-Is in DHF is discussed in Section 7.
6.1.2.2. Mineralocorticoid receptor antagonists Mineralocorticoid receptor antagonists have been shown to reduce the composite endpoint of HFH or death in patients with HF.43,254–257 The guideline Task Force decided to base recommendations on the primary endpoints. Although there were consistent reductions in the primary endpoint across the LVEF ranges studied, the individual endpoint of mortality was only reduced in HFrEF.43,254,256 There were differences in the mortality endpoints used in HFrEF and HFpEF trials, with all-cause mortality used in HFrEF trials and CV mortality used in HFpEF trials. Furthermore, different RCTs have included patients with different LVEF ranges not entirely consistent with the distinction between HFrEF and HFpEF. Whereas spironolactone was studied across LVEF ranges, eplerenone was only studied in HFrEF (LVEF up to 35%) and finerenone in patients with LVEF >40%. Although finerenone reduced the composite endpoint of HFH and CV mortality in the FINEARTS-HF trial, spironolactone did not in the overall results of the TOPCAT trial.255,257 However, a meta-analysis demonstrated a significant effect of the MRAs used in FINEARTS-HF and TOPCAT on the primary endpoint of HFH and CV mortality in patients with LVEF >40%.43 Mineralocorticoid receptor antagonists are chemically and structurally different; they block the receptors that bind aldosterone with different affinity and distribution in the heart and
kidneys and also block other steroid hormones with different degrees of affinity (e.g. corticosterone blockade) (see Supplementary data online, Table S3).258 Eplerenone and the non-steroidal MRA finerenone are more mineralocorticoid receptor-specific and therefore induce less gynaecomastia. Caution should be exercised when MRAs are started in patients with impaired kidney function (MRAs have not been tested in patients with eGFR <25 mL/min/1.73 m2) and in those with potassium levels ≥5.0 mmol/L.259 In patients taking MRAs whose serum potassium is >5.5 mEq/L, there might be an indication for dose reduction of the MRA or temporary discontinuation of the MRA to avoid life-threatening hyperkalaemia. The first step would be to recheck potassium levels. If the MRA dose is reduced or temporarily discontinued, the drug should be restarted if hyperkalaemia resolves. Practical guidance in the use and uptitration of MRAs are provided in Supplementary material online, Table S8.
6.1.3. Additional medical therapy in all patients with heart failure, independent of left ventricular ejection fraction 6.1.3.1. Loop diuretics Loop diuretics are recommended to reduce signs and/or symptoms of congestion in patients with HF and volume overload. Their effects on morbidity and mortality have not been studied in adequately powered RCTs. However, the major diseasemodifying treatment trials for HF were always conducted with a high background use of loop diuretic therapy. One meta-analysis has shown that in patients with HF, diuretics appear to reduce the risk of death and WHF compared with a placebo, and compared with an active control, diuretics improved exercise capacity.260 Several observational studies have linked loop diuretic use to higher mortality, even after adjustment or propensity matching.261 However, several biases remain as sicker patients are generally prescribed higher doses of loop diuretics. Clearly, patients benefit from maintenance therapy with a loop diuretic to prevent or control congestion. However, the use of loop diuretics may result in electrolyte disturbances, further neurohormonal activation, accelerated kidney function decline, and symptomatic hypotension. The latter may be especially relevant as it could result in treatment with lower doses of FMT. It is generally advised to use the lowest possible dose of diuretics to maintain euvolaemia. Importantly, the individual diuretic dose may change significantly over time.262 Therefore, dynamic and individualized dosing of loop diuretic is recommended.263,264 The use of a multiparameterbased evaluation to assess congestion, using clinical assessment at rest and during dynamic manoeuvres, as well as biomarkers (eGFR, electrolytes, natriuretic peptides), supplemented with imaging assessment according to local expertise, is probably the best contemporary strategy to optimize diuretic dosing.265 Optimal FMT and GDIT often results in less need for diuretic treatment.266,267 The chronic use of thiazide diuretics in stable patients should be avoided, as this often induces severe electrolyte disturbances that could go undetected in the ambulatory setting. Treatment of DHF and approach to diuretic treatment in this setting is covered in Section 7.
6.1.3.2. Potassium binders Hyperkalaemia is common in HF, often as a result of comorbidities (e.g., diabetes, CKD), concomitant use of renin–angiotensin– aldosterone system inhibitors (ACE-Is/ARNIs/ARBs and MRAs),
6.1.2. Foundational medical therapy in all patients with heart failure, independent of left ventricular ejection fraction
Page 33 · PDF
6.1.4. Foundational medical therapy for heart failure with reduced ejection fraction Modulation of the renin–angiotensin–aldosterone system, sympathetic nervous systems, and sodium–glucose co-transporter (SGLT2) inhibition has been shown to improve survival, reduce the risk of HFH, and reduce symptoms in patients with HFrEF. Treatment with optimal FMT, including ACE-Is/ARNIs/ARBs, beta-blockers, MRAs, and SGLT2-Is, is recommended as the foundation of treatment for all patients with HFrEF. There is no evidence favouring any particular sequencing during initiation and uptitration. Therefore, the consensus is that FMT can be commenced together with individual variations based on clinical assessment as soon as the diagnosis of HFrEF is established. Drugs should be uptitrated and continued at the doses used in the RCTs (or to the highest tolerated doses). Misinterpretation of changes in kidney function is a leading cause of insufficient dosing or inappropriate discontinuation of FMT and should be avoided (Section 6.1.6).273 Additional medical therapy may be used in selected patients with HFrEF (see Section 6.1.5). No large prospective RCT has been performed exclusively in patients with LVEF 41%–49%. Patients with LVEF 41%–49% appear to respond to FMT, similar to patients with LVEF <40%.36,38–41 Many patients with LVEF 41%–49% may already be on ACE-Is or ARBs and beta-blockers for other CV indications such as CAD, hypertension, or post-MI LV systolic dysfunction. Sodium–glucose co-transporter 2 inhibitors and MRAs are recommended for all ranges of LVEF, as covered in Section 6.1.2. The recommended doses of FMT and AMT are provided in Table 11. Practical guidance in the use and uptitration of FMT are provided in Supplementary material online, Tables S4–S9.
6.1.4.1. Angiotensin-converting enzyme inhibitors and angiotensin receptor–neprilysin inhibitor Angiotensin-converting enzyme inhibitors were the first class of drugs shown to reduce mortality and morbidity and to improve symptoms in patients with HFrEF.137,138,274–277 They are
recommended in all patients with HFrEF unless contraindicated or not tolerated and should be uptitrated to the highest recommended doses. If these doses are not tolerated, intermediate doses should be tried. In the higher end of LVEF, evidence is limited. The PEP-CHF trial (perindopril) was conducted in patients with an LVEF >40%, but it did not report outcomes according to LVEF.39 The PEACE trial reported a subgroup analysis showing a reduction in mortality with trandolapril in patients with LVEF from 40% to 50%.38 An ARNI is composed of an ARB and an inhibitor of neprilysin, an enzyme that degrades natriuretic peptides, bradykinin, adrenomedullin, and other vasoactive peptides. In the PARADIGM-HF trial, the ARNI, sacubitril–valsartan, was compared with enalapril in symptomatic patients with HFrEF who already tolerated an adequate dose of either an ACE-I or an ARB.278 ARNI significantly reduced the composite endpoint of CV death or HFH by 20% as compared with enalapril.278 Additional benefits included improvement in QoL, reduction in decline of eGFR, a reduction in loop diuretic dose, and lower risk of hyperkalaemia.279,280 If patients continue to have chronic symptomatic HFrEF and they tolerate an ACE-I or an ARB, it is recommended that they be switched to an ARNI to reduce morbidity and mortality. Pre- and post-discharge initiation of ARNIs in HFrEF patients have shown similar efficacy and safety, and larger NT-proBNP reductions compared with ACE-I treatment ̈ patients.281–283 As such, the use of an in ACE-I/ARB naive ARNI may be efficacious as de novo treatment in patients with symptomatic chronic HFrEF to simplify management and maintain eGFR and QoL. Use of an ARNI is more frequently associated with symptomatic hypotension, and a washout period of at least 36 h after ACE-I therapy is required to minimize the risk of angio-oedema. Treatment with ACE-Is or ARNIs is indicated, but should be given with caution, to patients with low blood pressures (systolic blood pressure <100 mmHg), kidney insufficiency (eGFR <30 mL/min/ 1.73 m2), or elevated serum potassium (>5.2 mEq/L). Abrupt withdrawal of ACE-Is or ARNIs can lead to clinical deterioration and should be avoided, and in those patients for whom treatment with an ARNIs is not possible, continued use of an ACE-I remains strongly advised.
6.1.4.2. Angiotensin II type 1 receptor blockers Angiotensin II receptor blockers are recommended for HFrEF patients who cannot tolerate ACE-Is or ARNIs due to side effects. Unlike ACE-Is, ARBs do not inhibit kininases and are associated with a much lower incidence of cough and angio-oedema. In the CHARM-Alternative study, candesartan reduced CV death and HFH in patients who were not receiving an ACE-I due to previous intolerance.284 In the HEAAL study, high-dose losartan reduced HFH compared with low-dose losartan in ACE-I intolerant patients.285 Valsartan, in addition to usual therapy, including ACE-Is, reduced HFH in the Val-HeFT trial.286 However, no ARB has reduced all-cause mortality in any trial, and combination with an ACE-I increases adverse effects. Also, in patients with higher LVEF, evidence is limited. The CHARM-Preserved trial did not show a reduction in its primary endpoint of CV death or HFH, but a retrospective analysis showed that candesartan reduced the number of patients hospitalized for HF among those with LVEF 40%–49%.40,41
and because of HF itself. Hyperkalaemia may increase the risk for arrhythmias and death.268 Hyperkalaemia, and the fear of inducing it, often results in under-utilization, dose reductions, or discontinuation of ACE-Is/ARNIs/ARBs and MRAs compromising their cardio-kidney benefit in HF. The gastrointestinal potassium binders patiromer and sodium zirconium cyclosilicate remove potassium by exchanging cations, leading to increased faecal excretion. Both agents have shown favourable results to treat and/or prevent hyperkalaemia in patients receiving ACE-Is/ARNIs/ ARBs and MRAs, therefore facilitating the continuation or uptitration of ACE-Is/ARNIs/ARBs and MRAs.269–272 Whether potassium binders improve clinical outcomes is still unclear. In the REALIZE-K trial, there was a signal towards more HF deterioration with sodium zirconium cyclosilicate as compared with placebo, although the trial was not powered to detect clinical outcomes.272 Potential adverse effects for the potassium binders include gastrointestinal symptoms (nausea, constipation, diarrhoea), hypomagnesaemia (for patiromer), and oedema (for sodium zirconium cyclosilicate). No specific recommendations for the use of potassium binders are included in the guideline at current time, due to insufficient evidence for clinical benefit.
Page 34 · PDF
6.1.5. Additional medical therapy for heart failure with reduced ejection fraction 6.1.5.1. If-channel inhibitor (ivabradine) Ivabradine should be considered in patients with symptomatic HFrEF who at rest are in sinus rhythm with heart rate ≥70 b.p.m., LVEF ≤35%, and recent HFH, despite stable FMT including optimized beta-blocker therapy.294 Ivabradine slows heart rate by inhibition of the If current. In the SHIFT trial, the primary composite endpoint of CV death or HFH was reduced, mainly driven by a reduction in HFH.294 Importantly, only 25% of patients studied in the trial were on optimal doses of betablockers.294 As beta-blockers have well-proven morbidity and mortality benefits, they should be initiated and uptitrated to target doses first, before assessing the resting heart rate for consideration of adding ivabradine.
6.1.5.2. Vericiguat The oral soluble guanylate cyclase stimulator vericiguat may be considered in patients with symptomatic HFrEF and LVEF <45% despite optimal FMT. The VICTORIA study assessed the efficacy and safety of vericiguat in patients with LVEF <45% and with recent episodes of WHF, who were already on the highest tolerated FMT. The incidence of the primary endpoint of CV death or HFH was lower among those who received vericiguat than among those who received placebo.295 There was no reduction in either all-cause or CV death. The much higher event rate in VICTORIA compared with other RCTs in patients with HFrEF was associated with a shorter median follow-up to acquire the total number of events needed, which may explain why HFH were reduced, but CV
mortality was not significantly reduced.296 There was also heterogeneity in a subgroup analysis, with less benefit in patients with the highest NT-proBNP levels. The VICTOR study evaluated vericiguat in ambulatory patients with HFrEF (LVEF ≤40%) who did not have a recent WHF event and who were on contemporary FMT. VICTOR was neutral for the primary composite endpoint of time to CV death or HFH (HR 0.93; 95% CI 0.83–1.04; P = .22).297 Over a median follow-up of ∼18.5 months, CV death was numerically lower with vericiguat (9.6% vs 11.3%; HR 0.83; 95% CI 0.71–0.97), whereas HFH was similar between groups (11.4% vs 11.9%; HR 0.95; 95% CI 0.82– 1.10). The trial therefore did not confirm a primary composite benefit in a stable, well-treated ambulatory HFrEF population, although pooled analyses combining VICTOR and VICTORIA suggest benefit across the broader HFrEF spectrum. Also, there was a reduction in all-cause mortality, a secondary endpoint in the trials.298,299
6.1.5.3. Hydralazine and isosorbide dinitrate There is no clear evidence to recommend the use of hydralazine and isosorbide dinitrate in all patients with HFrEF. In a small RCT conducted in self-identified black patients the addition of the combination of hydralazine and isosorbide dinitrate to conventional therapy at that time (an ACE-I, a beta-blocker, and an MRA) reduced mortality and HFH, and improved QoL in patients with symptomatic HFrEF.300 It is unclear if a benefit of hydralazine and isosorbide dinitrate exists for non-black patients with HFrEF. Additionally, a combination of hydralazine and isosorbide dinitrate may be considered in symptomatic patients with HFrEF who cannot tolerate any of an ACE-I, an ARNI, or an ARB (or if they are contraindicated) to potentially reduce HFH and mortality. This recommendation is based on the results of the Veterans Administration Cooperative Study, which included only male patients with symptomatic HFrEF who were treated with only digoxin and diuretics.301
6.1.5.4. Cardiac glycosides Cardiac glycosides, digoxin or digitoxin, should be considered in patients with HFrEF to reduce the risk of HFH.302–304 In the DIG trial, the overall effect on mortality with digoxin was neutral but there was a reduction in HFH.303 Moreover, the effects of digoxin in patients with HFrEF and AF have not been studied in RCTs, but digoxin may be useful for the treatment of AF with rapid ventricular rate when other therapies cannot be used.305–307 A serum digoxin concentration <1.2 ng/mL should be used as a target during ongoing therapy.308 The DIGIT-HF trial examined whether low-dose digitoxin added to contemporary FMT improves outcomes in patients with chronic symptomatic HFrEF (LVEF ≤40% and NYHA class III/IV or LVEF ≤30% and NYHA class II).304 The trial included most patients in NYHA class III and, contrary to the DIG trial, also included patients with AF. They were randomized to digitoxin [starting 0.07 mg daily, then titrated to target serum concentrations (10.5–23.6 nmol/L)] vs placebo. Over a median follow-up of 36 months, the primary composite endpoint—death from any cause or HFH— occurred in 39.5% of the digitoxin group vs 44.1% of the placebo group (HR 0.82; 95% CI 0.69–0.98; P = .03). There was no significant reduction in all-cause mortality alone (27.2% vs 29.5%; HR 0.86; 95% CI 0.69–1.07) or in HFH alone (28.1% vs 30.4%;
Beta-blockers have been shown to reduce morbidity and mortality in patients with HFrEF in addition to treatment with an ACE-I and diuretics.36,287–292 Bisoprolol, sustained-release metoprolol (succinate), and carvedilol have been shown to reduce the risk of death in patients with HFrEF, whereas nebivolol only reduced the combined endpoint of all-cause mortality and CV hospitalization. An individual patient meta-analysis of RCTs of beta-blockers suggested similar reductions in CV and allcause mortality for patients in sinus rhythm with HFrEF who had LVEF <40% and LVEF 40%–50%.36 Beta-blockers should be initiated early in clinically stable patients, at low doses and gradually uptitrated to the highest tolerated dose. In patients admitted with DHF, beta-blockers should be cautiously initiated in hospital, once the patient is haemodynamically stabilized. Every effort should be made to achieve the target doses of the beta-blockers shown to be effective in major clinical trials (Table 11). Even if symptoms do not improve, long-term treatment should be maintained to reduce the risk of major CV events. The effect of beta-blockers in patients with HFrEF and AF remains uncertain. A retrospective subgroup individual-patient data meta-analysis of all major beta-blocker trials in HFrEF showed no benefit on hospital admissions and mortality in the subgroup of patients with HFrEF with AF.36,293 However, to date no RCT has ever been conducted investigating the effect of beta-blockers specifically in patients with AF and HFrEF, despite beta-blockers being potentially useful for rate control of AF.
Page 35 · PDF
HR 0.85; 95% CI 0.69–1.05).304 Taken together, available evidence suggests that cardiac glycosides (digoxin or digitoxin), when added to FMT, can reduce the risk of HFH in patients with chronic symptomatic HFrEF. Both agents share a narrow therapeutic window and require careful monitoring but differ in their metabolic elimination: digoxin is primarily eliminated through the kidneys, whereas digitoxin undergoes hepatic elimination.
Omecamtiv mecarbil, a cardiac myosin activator, reduced the risk of HF events modestly in the GALACTIC-HF trial, but without a significant mortality benefit. The drug is not currently approved for clinical use in HF.309
6.1.6. The importance of uptitrating foundational medical therapy and maintaining adherence in heart failure with reduced ejection fraction Foundational medical therapy is essential in HFrEF and must be initiated and uptitrated to target (Table 11) or highest tolerated doses.306,307 A practical guidance for the use of medical therapies is available in Supplementary data online, Tables S4–S9. Randomized controlled trials of medical therapy in HF initiated therapy at low doses, with protocol-driven uptitration, irrespective of symptomatic improvement, unless limited by intolerance. The target doses used in these trials established the efficacy and safety of these therapies and therefore form the basis of guideline recommendations. When target doses are not achievable or tolerated, the maximal tolerated dose is recommended. Registry and real-life data have shown significant underimplementation of FMT in HFrEF, both with regard to number of drugs and doses used. Importantly, misinterpretation of changes in kidney function, leading to inappropriate discontinuation or down-regulation of doses of FMT, is a leading cause of insufficient FMT and should be avoided, both in decompensated and chronic HF.273,310 Many classes of FMT can safely be initiated in patients with lower eGFR (Supplementary data online, Tables S4–S9 and 2026 ESC Guidelines on cardiovascular disease and chronic kidney disease).122,259 No statistically significant interaction has been found between the presence of CKD and the treatment effect of the components of FMT on the primary endpoint of their respective trials.259 Therefore, in terms of relative risk reduction, these agents are equally effective in patients with CKD. Because patients with CKD are at the highest baseline risk for CV death or HFH, the absolute risk reduction effect is even more pronounced in patients with HF and CKD. Therefore, it is crucial that FMT is initiated, uptitrated, and maintained in patients with CKD.259 In trials that have evaluated dose responses for outcomes, composite event rates were lower with target doses compared with lower doses.274,311 Maintenance of FMT in patients with HFrEF is crucial for reducing the risk of HFH and improving survival and QoL. Even if symptoms and/or LVEF improve, it is recommended that optimal FMT is continued as lifelong treatment. Only in very selected cases of HFrEF with complete normalization of LV volumes and LVEF, including natriuretic peptides and in the
6.1.7. Pharmacological therapy for heart failure with preserved ejection fraction Foundational medical therapy for HFpEF includes SGLT2-Is and MRAs, as covered in Section 6.1.2. Heart failure with preserved ejection fraction differs from HFrEF as patients tend to be older, and more often female with a high burden of comorbidities including AF, CKD, obesity, diabetes, and non-CV comorbidities.313,314 There are numerous potential causes of HFpEF and, as the pathophysiology of various HFpEF syndromes differ, they also require distinct individualized therapies. Furthermore, it is important to exclude other conditions that might mimic the HFpEF syndrome (e.g. HCM, amyloidosis) or realize that certain diseases have similar symptoms but may coexist with HFpEF (pulmonary disease, anaemia, obesity, and deconditioning). There are Class I recommendations for SGLT2-Is and MRAs to be used in all symptomatic patients with HF, and diuretics to be used to treat signs and symptoms of congestion. Other pharmacological agents, such as ACE-Is, ARBs, and betablockers, may be used particularly for comorbidities, as there is uncertainty of the effect on morbidity and mortality. Recently, in RCTs, treatment with the GLP-1 RA semaglutide or the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA tirzepatide improved QoL in addition to weight reduction in patients with HFpEF and obesity, independently of diabetes status (see Section 10).315–317
6.1.7.1. Angiotensin receptor–neprilysin inhibitors In the PARAGON-HF trial, sacubitril–valsartan compared with valsartan did not achieve a significant reduction in the primary composite endpoint of CV death or total HFH in patients with symptomatic HF and LVEF ≥45%.42 There was a reduction in
6.1.5.5. Cardiac myosin activator
context of a clear treatable reversible cause of HF, gradual discontinuation may be considered. Non-adherence to FMT can be multifactorial. Patient-related factors such as side-effects, drug interactions, economic difficulties, psychosocial issues, or poor health literacy may be contributing factors. However, healthcare-related inappropriate discontinuation of FMT should not be neglected. In general, incurrent illness or infections without haemodynamic compromise should not lead to down-titration or discontinuation of FMT. Asymptomatic or tolerable hypotension should not lead to downtitration or discontinuation of FMT but may require re-evaluation of diuretic use. It is recommended that patients with HFrEF and CKD maintain FMT, as several trials have shown beneficial effects on kidney endpoints as well as CV endpoints.312 However, temporary discontinuation of MRAs/ARNIs/ACE-Is/ARBs and SGLT2-Is may be needed in cases with acute kidney injury and eGFR <15 mL/min/1.73 m2. Severe hyperkalaemia (potassium >5.5 or >6 mmol/L) should lead to temporary down-titration or discontinuation of MRAs and/or ARNIs/ACE-Is/ARBs (see Supplementary data online, Tables S4, S5 and S9). Temporary discontinuation of beta-blockers and ARNIs/ACE-Is/ARBs is advised in patients with severe haemodynamic instability. If FMT has been temporarily discontinued for less than 14 days, it should, in most cases, be safe to initiate FMT directly at the previously tolerated doses in stable patients. Euvolaemia is important prior to initiating beta-blockers.
Page 36 · PDF
6.1.8. Pharmacological treatment in heart failure with improved ejection fraction In patients with HFrEF, FMT and GDIT can result in improvement in symptoms, functional capacity, NT-proBNP levels and LVEF (i.e. reverse remodelling). However, in most patients, LV function and structural abnormalities do not fully normalize, and symptoms and biomarker abnormalities may persist or reoccur. Many patients deemed to have recovered from HFrEF with resolution of symptoms and improvement of LVEF and natriuretic peptide levels will relapse after withdrawal of FMT. TRED-HF was a small open-label trial in which phased withdrawal of FMT was conducted in patients with HFrEF and DCM whose LVEF had improved (but not necessarily normalized—from LVEF <40% to LVEF at least 50%) after treatment with FMT , their LV volume
had normalized, and the NT-proBNP concentrations were reduced to <250 ng/L. Withdrawal of FMT resulted in relapse of HFrEF in 40% of the patients within 6 months, warranting reinitiation of therapy.321,322 In contrast, the CATHEDRAL-HF trial—a single-centre, open-label pilot study—randomized 60 patients with similar characteristics to those in the TRED-HF trial to either phased withdrawal of FMT (excluding carvedilol) or continued FMT. Phased withdrawal did not result in a higher rate of HFrEF relapse.323,324 Taken together, there is no solid evidence at this time to suggest that resolution of symptoms and improvement in cardiac function and biomarkers after treatment reflects actual recovery but, rather, remission, which requires FMT to be maintained. Some causes of HF might be reversible (e.g. Takotsubo syndrome, arrhythmia-associated HF, myocarditis, HF caused by abnormal cardiac conduction). In these patients, where a completely reversible cause of HF is suspected and where complete normalization of LV function and volume has occurred after treatment of the reversible cause, including normalization of natriuretic peptides, a gradual trial of FMT withdrawal might be considered. However, this may be considered with caution and only in exceptional cases upon the request of the patient. The open-label, single-centre STOP-CRT trial indicated that gradual neurohumoral blocker withdrawal (and thus a CRT-only strategy) was feasible and safe in a small number of very selected patients with normalized LVEF after CRT.325 Such withdrawal should only be done under frequent clinical, laboratory, and imaging control to rule out relapse of HF. One should take into consideration that often coexisting comorbidities warrant continuation of FMT. However, more and larger RCTs in this domain are needed to assess the clinical effect of withdrawal of each component of FMT in patients with HFrEF and improved LVEF.
Evidence-based doses of disease-modifying drugs in key randomized trials in patients with heart failure
ARNIs Sacubitril–valsartan ARBs Candesartan
Metoprolol succinate (CR/XL)
total HFH (rate ratio 0.85; 95% CI 0.72–1.00; P = .056) that also did not meet statistical significance. A meta-analysis of the PARADIGM-HF and PARAGON-HF trials showed a benefit of sacubitril–valsartan compared with valsartan in patients with an LVEF below 60-65%.318,319 ARNIs therefore may be considered in HFpEF, especially in those with lower LVEF ranges. Although renin–angiotensin system inhibition strategies with ACE-Is and/or ARBs have been successful in the treatment of HFrEF, clinical trials have not shown a clear benefit in HFpEF patients. In a meta-analysis of four trials evaluating ARBs in patients with HFpEF, there was no signal for benefit on CV death (HR 1.02), all-cause death (HR 1.01; 95% CI 0.92–1.11), or HFH (HR 0.92; 95% CI 0.83–1.02).320 Candesartan was associated with a reduction in recurrent HFH until LVEF was over 60%.40 Although no strong recommendation is given to start these agents in patients with HFpEF, many have coexisting indications for ACE-I/ARB therapy (hypertension/diabetes/CKD).
Page 37 · PDF
Non-steroidal Finerenone SGLT2-Is
Hydralazine/isosorbide dinitrate
37.5 mg t.i.d./20 mg t.i.d.
The table provides initiation and target doses of FMT and AMT. For practical guidance in use of the different drugs, see Supplementary data online, Tables S4–S9. ACE-I, angiotensin-converting enzyme inhibitor; AMT, additional medical therapy; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; b.i.d., bis in die (twice daily); CR, controlled release; CV, cardiovascular; eGFR, estimated glomerular filtration rate; FMT, foundational medical therapy; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; o.d., omne in die (once daily); SGLT2-I, sodium–glucose co-transporter 2 inhibitor; t.i.d., ter in die (three times a day); XL, extended release. a Indicates an ACE-I where the dosing target is derived from post-MI trials. b Indicates drugs where a higher dose has been shown to reduce morbidity/mortality compared with a lower dose of the same drug, but there is no substantive randomized, placebo-controlled trial and the optimal dose is uncertain. c Sacubitril–valsartan may have an optional lower starting dose of 24/26 mg twice daily for those with a history of symptomatic hypotension, ACE-I naïve patients and patients with eGFR 30–60 mL/min/1.73 m2. d A maximum dose of 50 mg twice daily can be administered to patients weighing over 85 kg. e Indicates a treatment not shown to reduce CV or all-cause death in patients with heart failure (or shown to be non-inferior to a treatment that does). f Spironolactone has an optional starting dose of 12.5 mg in patients where kidney status or hyperkalaemia warrant caution. g Finerenone has a different starting and target dose according to eGFR (10–20 mg, if eGFR ≤60 mL/min/1.73 m2; 20–40 mg, if eGFR >60 mL/min/1.73 m2). h Digoxin/digitoxin should be titrated according to plasma levels.
Recommendation Table 5 — Recommendations for pharmacological management of chronic heart failure (see Evidence Tables 29–41) Classa
A beta-blocker is recommended in stable patients with symptomatic HFrEF to reduce the risk of HFH and death.e 36,287–293,330
An ACE-I or ARNI is recommended in patients with symptomatic HFrEF to reduce the risk of HFH and death.e 274–278
An ARB is recommended in patients with symptomatic HFrEF to reduce the risk of HFH and CV death if they are unable to tolerate an ACE-I or ARNI.e 284–286,331
A cardiac glycoside (digoxin or digitoxin) should be considered in patients with symptomatic HFrEF with LVEF ≤40%, despite optimal FMT, to reduce the risk of HFH.303,304
Recommendations All patients with HF, independent of LVEF An SGLT2-I (dapagliflozin or empagliflozin) is recommended in patients with symptomatic HF independent of LVEF to reduce the risk of HFH or CV death.241–245,326 An MRA (sMRA for HFrEF and sMRA/nsMRA for HFpEF) is recommended in patients with symptomatic HF independent of LVEF to reduce the risk of HFH or CV death.c43,254–257 Dynamic individualized dosing of loop diuretics according to volume status is recommended in patients with HF and signs and/ or symptoms of congestion to alleviate HF symptoms, improve exercise capacity, and reduce the risk of HFH.d 327–329 Uptitration of FMT at least every 1–2 weeks in patients with HF, guided by symptoms, vital signs, and laboratory findings, to achieve optimal target doses shown to be efficacious in RCTs is recommended to reduce the risk of HFH or death.274,311 Continuation of FMT at the highest tolerated doses is recommended in all patients with HF, including those who become asymptomatic or with LVEF improvement, in order to reduce the risk of HFH and death.321 HFrEF
Switching from an ACE-I or ARB to an ARNI is recommended in patients with symptomatic HFrEF to reduce the risk of HFH and death.e 278
Page 38 · PDF
Ivabradine should be considered for patients with symptomatic HFrEF, LVEF ≤35%, in sinus rhythm, resting heart rate >70 b.p.m., on the highest tolerated ACE-I/ARNI, MRA, SGLT2-I, and beta-blockers to reduce the risk of HFH or CV death.294 Ivabradine should be considered in patients with symptomatic HFrEF, LVEF ≤35%, in sinus rhythm, who are unable to tolerate a beta-blocker, on the highest tolerated ACE-I/ARNI and MRA to reduce the risk of HFH or CV death.294 Hydralazine and isosorbide dinitrate should be considered in self-identified black patients with symptomatic HFrEF with LVEF ≤40% on top of optimal FMT to reduce the risk of HFH and death.300 Hydralazine and isosorbide dinitrate may be considered in patients with symptomatic HFrEF with LVEF ≤40% who cannot tolerate ARNI, ACE-I, or ARB to reduce the risk of HFH and death.301 reduce the risk of HFH and CV death.295,297,298
selected patients who are asymptomatic with complete normalization of LV function and volume as well as natriuretic peptide levels after specific treatment of reversible causes of HF, in order to accommodate patient preference.325 HFpEF ACE-I/ARB/ARNI may be considered in patients with symptomatic HFpEF to reduce the risk of HFH.39,40,42,319,332–337
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; CV, cardiovascular; FMT, foundational medical therapy; HF, heart failure; HFH, heart failure hospitalization; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LV, left ventricular; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; nsMRA, non-steroidal mineralocorticoid receptor antagonist; RCT, randomized clinical trial; SGLT2-I, sodium–glucose co-transporter 2 inhibitor; sMRA, steroidal mineralocorticoid receptor antagonist. a Class of recommendation. b Level of evidence. c The evidence for using MRAs in patients with HFrEF is based on RCTs conducted with sMRAs (spironolactone and eplerenone), whereas the evidence for patients with HFpEF originates from a meta-analysis of RCTs using both steroidal (spironolactone) and non-steroidal MRAs (finerenone). d This recommendation is considered by the Task Force to have level of evidence A due to clear clinical effectiveness. Dynamic dosing of loop diuretics has been widely accepted as effective and therefore no adequately powered RCTs have ever been conducted or are likely to be conducted for ethical reasons. e No large prospective RCT has been performed on the use of beta-blockers, ACE-I/ARNI/ARB exclusively in patients with LVEF 41%–49%.
6.2. Guideline-directed interventional therapies for chronic heart failure The term GDIT includes all guideline-directed interventional therapies for HF (see Section 3). In this section, we provide recommendations for ICDs and CRT. Other implantable devices, for which recommendations have not been made, will be discussed at the end of this section. Section 7 provides recommendations for interventional therapies in the setting of DHF, and Section 8 provides recommendations for interventional therapies in the setting of advanced HF. Section 9 covers comorbidityspecific interventional therapies.
6.2.1. Implantable cardioverter-defibrillators The recognition that arrhythmic sudden cardiac death (SCD) accounted for ∼30%–60% of all deaths in the early HF trials338 paved the way for the use of ICDs in patients with HFrEF. Antiarrhythmic drugs, such as amiodarone and dronedarone, are effective in reducing ventricular arrhythmias, but they do not prolong survival and may shorten it.339,340 In contrast, ICDs are effective in preventing SCD and prolonging survival in patients with HFrEF who are at high risk of SCD.340–344
6.2.1.1. Secondary prevention of sudden cardiac death Unlike antiarrhythmic drugs such as amiodarone, ICDs reduce mortality in cardiac arrest survivors and those with sustained ventricular arrhythmias, regardless of LVEF or presence of HF.345–348 Recommendations for secondary prevention ICD implantation are provided in the 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the
prevention of sudden cardiac death.119 Cardiomyopathy-specific recommendations for secondary prevention ICD implantation are provided in the 2023 ESC Guidelines for the management of cardiomyopathies.124
6.2.1.2. Primary prevention of sudden cardiac death in heart failure In the SCD-HeFT trial, compared to amiodarone, ICD reduced allcause death by 23% in patients with HFrEF.340 In MADIT-II, 1232 patients were randomized to an ICD or control, and ICD therapy reduced all-cause death by 31%.342 Although the risk of SCD has declined over time, the residual risk of SCD is still high (annual rate of 3.3 per 100 patient-years in PARADIGM-HF), warranting primary prevention ICD implantation in patients with HFrEF deemed at high risk of SCD.349 For details, see Supplementary data online, Section S3.1.1.1.340,342,349–352
6.2.1.3. Patient selection for implantable cardioverter-defibrillator therapy Selection of patients with HFrEF for ICD implantation should be based on LVEF thresholds established in RCTs and underlying aetiology, as individuals with non-ischaemic HF may derive less benefit than those with ischaemic heart disease.341,343,353,354 However, a meta-analysis of RCTs demonstrated an overall survival benefit, even in patients with non-ischaemic HF.344 The effect of ICD treatment depends on the competing risk of non-sudden death, both CV and non-CV. Thus, in patients with many comorbidities and older age, the benefit of ICD therapy may be substantially lower.355 Shared decision-making is essential when considering ICD implantation in patients with HF.
Gradual discontinuation of FMT under frequent clinical, laboratory, and imaging surveillance may be considered in highly
Vericiguat may be considered in patients with symptomatic HFrEF and LVEF <45% despite treatment with optimal FMT to
Page 39 · PDF
Both patient preferences and clinical factors should be carefully considered. Individualized patient information on the potential risks and benefits should be provided to support an informed decision. The presence and the extent of myocardial fibrosis, genotypes, and additional factors may help arrhythmic risk stratification in patients with cardiomyopathies.124,356,357
Recommendation Table 6 — Recommendations for implantable cardioverter-defibrillator implantation (see Evidence Tables 42–48) Recommendations
An ICD is recommended in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability (secondary prevention), and who are expected to survive for >1 year with good functional status, in the
Two studies have shown that primary prevention ICD implantation within 40 days of an MI does not improve outcomes.358,359 A 3-month period after uptitration of FMT before considering ICD implantation is reasonable. Delaying ICD implantation carries a risk of SCD at 2%–4% by 6 months and ∼7% by 1 year.360
absence of reversible causes, or unless the ventricular arrhythmia has occurred <48 h after
As with FMT, the commitment to GDIT is in most cases lifelong. Implantation of an ICD commits the patient to lifelong monitoring and the need for generator replacements. The lifelong risk of complications should be considered in the decision to implant. A further question is whether ICD generators should be replaced in patients who have not had appropriate ICD therapies. ICD shocks occur in more than 15% of patients after generator replacement in those who have not had an appropriate ICD shock during the lifetime of their first ICD generator.361 Even in patients with LVEF improvement after FMT and CRT, a considerable residual risk of SCD remains.362,363 As HFrEF and comorbidities progress, the benefit of ICD therapy may diminish. The need for ICD and the risk of SCD should be reconsidered over time and prior to every generator replacement, taking risk of SCD, remaining lifespan of the patient, risk of complications, competing risks of death due to comorbidities, frailty, and patient choice into account.364–367
6.2.1.6. Non-transvenous implantable cardioverter-defibrillator and wearable cardioverter-defibrillator In a subcutaneous ICD (S-ICD), the lead is extravascular and, therefore, not prone to intravascular infection. It is particularly attractive in patients with difficult venous access or those who are at risk of infection. The S-ICD is comparable to transvenous ICDs in terms of efficacy, complication rates, and inappropriate shock rates.368,369 Importantly, the S-ICD cannot treat bradyarrhythmia (other than post-shock pacing) and does not provide anti-tachycardia pacing. The extravascular ICD consists of a generator implanted in a subfascial or submuscular pocket and a substernally deployed lead.370 A notable advantage over the S-ICD is that the generator is similar in size to a transvenous ICD. Long-term data on efficacy and safety are required. A wearable defibrillator may be considered in patients deemed at especially high risk of SCD or as a bridge to decision for ICD implantation, although no mortality benefit has been shown in RCTs371,372 (see Supplementary data online, Section S3.1.1.2).
all-cause death.346 An ICD is recommended in patients with symptomatic HFrEF (NYHA class II/III) of an ischaemic aetiology (unless they have had an MI in the prior 40 days), and an LVEF ≤35% despite ≥3 months of optimal FMT, provided they are expected to survive longer than 1 year with good functional status, to reduce the risk of sudden death and all-cause death.340,342,373,374 An ICD should be considered in patients with symptomatic HFrEF (NYHA class II/III) of a non-ischaemic aetiology, and an LVEF ≤35% despite ≥3 months of optimal FMT, provided they are expected to survive longer than 1 year with good functional status, to reduce the risk of sudden death and all-cause death.340,341,344,375 Prior to generator replacement for CIEDs, a shared decision-making process between the patient and a cardiologist experienced in CIEDs and HF should be considered to ensure that the balance between risks and benefits still favour a CIED.376–380 A wearable cardioverter-defibrillator may be considered in patients with HF who are at risk of sudden cardiac death for a limited period in order to increase survival as a bridge to decision for permanent ICD implantation or while listed for heart transplantation.381–384 ICD implantation for primary prevention is not recommended within 40 days of an MI as implantation during this period does not 358,359
ICD implantation is not recommended in patients in NYHA class IV with severe symptoms refractory to pharmacological therapy unless they are candidates for CRT, a ventricular assist device, or heart transplantation.374,385–387 CIED, cardiac implantable electronic device; CRT, cardiac resynchronization therapy; FMT, foundational medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association. a Class of recommendation. b Level of evidence.
6.2.1.5. Implantable cardioverter-defibrillator generator replacement
an MI, to reduce the risk of sudden death and
6.2.1.4. Timing of implantable cardioverter-defibrillator therapy
Page 40 · PDF
40 6.2.2. Cardiac resynchronization therapy
6.2.2.1. Cardiac resynchronization therapy for heart failure caused by abnormal cardiac conduction Heart failure associated with abnormal cardiac conduction is defined as LV dysfunction due to conduction abnormalities (Figure 9 and Section 5.3.3). In patients with HF, where no other cause of HF other than abnormal cardiac conduction can be found, and there is a low likelihood of LVEF improvement, planning for CRT implantation may be considered early—even before full FMT uptitration.
6.2.2.2. Right ventricular pacing-induced heart failure As expected from the effects of ectopic cardiac stimulation, RV pacing leads to HFrEF in some patients.202,413 The incidence of pacemaker- or RV pacing-induced HF varies between 5.9% and 39%, depending on the definition.202,236–239 In the recent BUDAPEST-CRT Upgrade trial, upgrading to CRT-D significantly reduced death and HFH in patients with ≥20% RV pacing burden and QRS ≥150 ms (HR 0.27; P<.001). The BUDAPEST-CRT Upgrade trial is the first RCT and included only 360 patients in total. Therefore, CRT-D upgrade should be considered in such patients.202,237,238,412,414
6.2.2.3. Timing of cardiac resynchronization therapy implantation The timing of CRT in relation to hospitalizations has not been addressed by RCTs. In an observational study of 64 968
Figure 10 Indications for cardiac resynchronization therapy in heart failure. CRT, cardiac resynchronization therapy; FMT, foundational medical therapy; HFrEF, heart failure with reduced ejection fraction; ICD, Implantable cardioverter-defibrillator; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction. In the decision on device implantation consider the following: patient preference, likely benefit of ICD/CRT at the patient’s age, frailty and comorbidities, risk of complications, venous access issues. aUptitration to the highest tolerated doses of HFrEF FMT (see Table 11). bInitiation of FMT and planning for CRT implantation may be considered simultaneously in patients with symptomatic HFrEF, an LBBB with QRS ≥150 ms, and LVEF ≤35%, to improve symptoms and reduce morbidity and mortality, although reassessment of LVEF should be conducted prior to CRT implantation. (Class IIb).
In carefully selected patients with HFrEF, CRT improves cardiac function, QoL, and reduces hospitalizations and death. Landmark RCTs support CRT use across a range of HF severity.388–398 The first RCT to address the effects of CRT on morbidity and mortality was COMPANION388 in which CRT with pacemaker (CRT-P) and CRT with defibrillator (CRT-D) reduced the composite endpoint of all-cause death and hospitalizations for any cause by 20%. A reduction in all-cause death was shown with CRT-D, but not with CRT-P. In contrast, in the CARE-HF trial,392 which randomized participants to medical therapy with or without CRT-P, CRT-P reduced all-cause death and HFH. In the MADIT-CRT trial, in which 1820 patients in NYHA classes I and II were randomized to CRT-D or ICD, CRT-D reduced allcause death or HF events by 34%.397 In the REVERSE trial,396 which also involved patients in NYHA classes I and II with primary prevention ICD indications, CRT improved LVEF and reduced HFH. Importantly, in the 5-year follow-up of REVERSE, annualized death was low at 2.9% in patients randomized to ‘CRT-on’.399 Together, these findings have provided compelling evidence for using CRT across the spectrum of severity of HFrEF. For landmark trials of CRT, see Supplementary data online, Table S10.388,389,392,396–398,400–412 Figure 10 provides an overview of factors to consider when evaluating patients for CRT.
Page 41 · PDF
Recommendation Table 7 — Recommendations for cardiac resynchronization therapy implantation (see Evidence Tables 49–58) Recommendations
CRT is recommended in patients with symptomatic HFrEF, LVEF ≤35%, despite optimal FMT, in SR with LBBB and QRS duration ≥150 ms in order to improve symptoms and reduce the risk of hospitalizations and death.388– An upgrade to CRT should be considered in patients with an LVEF ≤35% who have received
optimal FMT and who have a significant proportion of RV pacing in order to reduce the risk of HFH or death.412
indication for ventricular pacing for high-degree AV block in order to reduce the risk of HFH and
death.409 CRT should be considered in patients with symptomatic HFrEF, LVEF ≤35%, despite optimal FMT, who are in SR with non-LBBB QRS morphology and QRS duration ≥150 ms in order to improve symptoms and reduce morbidity and death.388–398 CRT should be considered in patients with symptomatic HFrEF, LVEF ≤35%, despite optimal FMT, who are in SR with LBBB QRS morphology and QRS duration of 130–149 ms in order to improve symptoms and reduce
optimal FMT, who are in SR with non-LBBB QRS morphology and QRS duration of 130–149 ms
in order to improve symptoms and reduce morbidity and death.391,397 Initiation of FMT and planning for CRT implantation may be considered simultaneously in patients with symptomatic HFrEF, an LBBB with QRS ≥150 ms, and LVEF ≤35%, to improve symptoms and reduce morbidity and death, although reassessment of LVEF should be CRT is not recommended in patients with a QRS duration <130 ms who do not have an indication for pacing due to high-degree AV block.410,424,425
AV, atrioventricular; CRT, cardiac resynchronization therapy; FMT, foundational medical therapy; HF, heart failure; HFH, heart failure hospitalization; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverterdefibrillator; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; RV, right ventricular; SR, sinus rhythm. a Class of recommendation. b Level of evidence.
Conduction system pacing (CSP), including His bundle and left bundle branch area pacing, aims to engage the Purkinje network for rapid and synchronous LV activation.426 Left bundle branch area pacing may prove to be a feasible alternative to CRT when implantation is challenging. However, no RCT with patientcentred outcomes has evaluated the efficacy or long-term safety of CSP in HFrEF. Therefore, no recommendations can currently be made. See Evidence Table 22 and Supplementary data online, Section S3.1.3 for further details.427–433
morbidity and death.390,417 Continued
In the same way that FMT implies lifelong adherence to drugs, a CIED requires a lifelong commitment to device follow-up. For the clinician, skills in interpretation of device-derived electrograms, device-related problem solving, and programming are essential.434,435 For ICDs, routine defibrillation testing of shock efficacy does not reduce arrhythmic death and is therefore no longer recommended.436 Programming a high-rate cut-off and long detection intervals between detection of ventricular tachycardia and antitachycardia pacing or shocks dramatically reduce inappropriate shocks and unnecessary ICD therapy.436,437 At follow-up, the RV pacing burden as well as the intrinsic QRS duration are an important focus for deciding whether to upgrade from an ICD to a CRT-D device. In patients with a CRT device, regular follow-up and optimization should be implemented, as CRT programming and FMT may require further optimization after implantation.435 Appropriate programming of atrioventricular intervals and optimal LV lead vectors are required to optimize CRT response. In patients
conducted prior to CRT implantation.418–423
6.2.4. Cardiac implantable electronic device programming and follow-up
CRT, rather than RV pacing, should be considered in patients with HFrEF regardless of NYHA class or QRS width who have an
symptomatic HFrEF, LVEF ≤35%, despite
6.2.3. Conduction system pacing
a conventional pacemaker or an ICD and subsequently develop worsening HF despite
CRT may be considered in patients with
patients undergoing CRT, the combined endpoint of allcause death and HFH was lowest in patients with no HFH prior to implantation (9.7 per 100 person-years) and those who had CRT during the first HFH (11.1 per 100 personyears) compared with patients who had a CRT implantation within a year of their first HFH (17.3 per 100 patientyears).415 In a study of 15 619 CRT-eligible patients with HF in the Get With The Guidelines-HF registry, all-cause death was lower in those who received CRT implantation during HFH (adjusted HR 0.63; P<.0001) compared with patients who did not have CRT.416 A lower rate HF rehospitalization was observed in patients with CRT implanted during the first hospitalization (adjusted HR 0.64; P<.0001), but not in those prescribed CRT at discharge. As HFH is a critical step in the progression of HF, it may be beneficial to implant CRT at an early stage in patients who are most likely to benefit (LVEF ≤35%, LBBB with QRS ≥150 ms), ideally before an HFH has occurred.
Page 42 · PDF
42 with AF, the percentage of effective biventricular pacing (without fusion or pseudofusion) is an important focus. Further details on CRT follow-up and optimization are outlined in an HFA position paper.435
6.2.5. Other cardiac implantable electronic devices
6.2.6. Other implantable devices It has been hypothesized that an interatrial shunt could improve HF symptoms and outcomes by decompressing the left atrium. In the RELIEVE-HF study, 508 patients with HF and predominantly NYHA class III symptoms and any LVEF were randomized to transcatheter shunt implantation vs a sham procedure.442 After 2 years, no difference emerged in the primary effectiveness outcome [hierarchical composite ranking of all-cause death, cardiac transplantation or LV assist device (LVAD) implantation, HFH, outpatient WHF events, and change in QoL]. Importantly, patients with reduced LVEF had fewer adverse CV events with shunt treatment, whereas patients with HFpEF had more CV events. In the REDUCE LAP-HF II study in patients with LVEF ≥40%, the atrial shunt device was no better than the sham procedure in terms of the hierarchical composite of CV death or nonfatal ischaemic stroke at 12 months, rate of total HF events up to 24 months, and change in QoL at 12 months.443
7. Decompensated heart failure 7.1. Definition and epidemiology Decompensated HF is defined as acute or gradual onset of symptoms and/or signs of HF, severe enough to require urgent medical attention and treatment initiation or intensification. DHF can lead to an unplanned hospital admission, an emergency department visit, or an unplanned ambulatory visit requiring treatment for HF. DHF may present as either worsening of preexisting HF or as the initial manifestation of the disease (de novo HF). In the setting of patients with pre-existing HF, WHF is characterized by a deterioration in the symptoms and/or signs of HF and represents an event in HF progression, whereas DHF is specifically characterized by the requirement for treatment modification.444 Decompensated HF is associated with a high risk of death: 3%–10% during HF admission; 20%–30% at 1 year, >50% after 5 years.445–450 Compared to DHF occurring in patients with preexisting HF, de novo DHF may be associated with higher inhospital death, but lower post-discharge death and rehospitalization rates.451–453 Following a hospitalization for DHF, 1-year rehospitalization rates range between 35% and 44%.447,448,453–455 In addition, up to 50% of patients with HF
require intensification of treatment in the emergency service or in outpatient settings.456–462
7.2. Diagnosis Decompensated HF requires prompt diagnosis to ensure early treatment.463 If DHF is suspected, assessment of signs and symptoms of congestion and hypoperfusion must be done at the first medical contact. Non-invasive blood pressure, respiratory rate, pulse oximetry monitoring, body temperature measurement, and ECG should be performed early.464 In haemodynamically unstable patients with suspected hypoperfusion, assessment of serum lactate levels should be performed promptly.465 The currently recommended, non-age-adjusted, natriuretic peptide ‘rule-out’ thresholds for DHF are: NT-proBNP <300 pg/mL, or BNP <100 ng/mL, or MR-proANP <120 pg/mL.157,466–469 However, if clinical suspicion of HF remains despite values below ‘rule-out’ thresholds, specialist assessment and echocardiogram should be sought. Age-related thresholds for NT-proBNP, above which DHF is considered ‘likely’, are given in the footnote of Figure 11. In the older population, using the age-related NT-proBNP threshold may aid appropriate triage and help reduce unnecessary exams. NT-pro-BNP >5000 pg/mL indicates very high risk, and admission is generally recommended. For other laboratory tests and investigations for patients with suspected DHF, see Supplementary data online, Table S11. Initial investigations are carried out to diagnose DHF and rapidly detect any possible triggers. Transthoracic echocardiography should be performed in patients with high levels of NT-proBNP and in those for whom there is a high clinical suspicion of DHF. Where trained personnel are available, lung ultrasound identifies patients with pulmonary congestion and has utility in serial assessments.470–473
7.3. Clinical presentation Congestion and hypoperfusion are two major clinical manifestations of DHF.447,453 Congestion may stem from fluid overload, fluid redistribution, increased vascular permeability, and increased intracardiac pressures. Different clinical, laboratory, and imaging utilities should be used to assess congestion and its dynamic changes (see Supplementary data online, Table S12). Hypoperfusion is not a synonym for hypotension,474,475 although patients with DHF and hypotension also experience inadequate perfusion. An objective marker, serum lactate, may help identify patients with peripheral hypoperfusion and monitor therapy.465 Signs and symptoms associated with congestion and hypoperfusion are reported in Table 12. Four categories of DHF can be recognized based on clinical presentation: decompensated left-sided HF, decompensated right-sided HF, acute pulmonary oedema (APO), and cardiogenic shock (CS). Pathophysiology, timing of onset, and speed of deterioration differ between the four categories, but possible overlaps exist.
7.3.1. Decompensated left-sided heart failure Decompensated left-sided HF, in its classical clinical presentation, is characterized by a gradual onset of signs and symptoms with accumulating congestion as the primary pathophysiological process.476 It may occur in patients across the spectrum of LVEF and, in advanced stages, can lead to RV dysfunction and
In a small unblinded RCT, cardiac contractility modulation marginally improved peak oxygen uptake and QoL in patients with advanced HFrEF and a QRS <130 ms.438 In a small pilot study, cardiac contractility modulation improved the Kansas City Cardiomyopathy Questionnaire (KCCQ) score by 18 points in patients with HFpEF.439 No clinical outcome studies have emerged. Similarly, baroreceptor activation therapy led to improvements in 6-min walk distance and QoL in an unblinded RCT, but long-term clinical outcome data were neutral.440,441 Current evidence for these CIEDs is insufficient to support guideline recommendations. Although promising, these findings require confirmation in large, well-designed trials.439